Authors
Aymara Mas, Ph.D., Irene Cervelló, Ph.D., Claudia Gil-Sanchis, Ph.D., Amparo Faus, B.Sc., Jaime Ferro, M.D., Antonio Pellicer, M.D., Carlos Simón, M.D.
Vol 98, Issue 3, Pages 741-751.e6
Abstract
Objective:
To isolate and characterize human leiomyoma stem cells by Side
Population (SP) method.
Design:
Prospective experimental human and animal study.
Setting:
University research laboratory-affiliated infertility clinic.
Patients:
Women undergoing laparoscopic myomectomy.
Animals:
Female NOD-SCID mice.
Interventions:
Obtention of human leiomyoma SP cells as candidate tumorinitiating cells and establishment of two leiomyoma SP lines.
Main Outcome Measures:
Flow cytometry, semiquantitative polimerase chain reaction, clonogenicity assays, cDNA microarrays hybridization, cell culture, karyotype, molecular analysis, immunocytochemistry, in vitro differentiation, xenotransplantation assays, immunohistochemistry.
Results:
SP cells from human leiomyomas were isolated, identified and characterized. Two leiomyoma´s SP cell lines with a normal karyotype were thus established. Undifferentiated status was confirmed by the expression of OCT-4, NANOG, DNMT3B, GDF3. Presence of typical mesenchymal markers (CD90, CD105, CD73) and absence of hematopoietic stem cell markers (CD34, CD45) supported their mesodermal origin. Mesenchymal lineage commitment was also demonstrated by their ability to differentiate in vitro into adipogenic and osteogenic lineages. Finally, their functional capability was established in an animal model by leiomyoma tissue reconstruction.
Conclusion:
SP cells from human leiomyoma exhibit key features of tumorinitiating cells opening up new possibilities to understand the origin and develop new non-surgical approaches for leiomyomas.
Read the full text at: http://www.fertstert.org/article/S0015-0282(12)00499-2/fulltext
Please sign in or register for FREE
Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.